Skip to content

Research & Culture6 min readBy Lola · Updated November 11, 2026

"Like a Shroud Had Been Lifted": Patients Describe High-Dose Psilocybin Sessions

"Like a Shroud Had Been Lifted": Patients Describe High-Dose Psilocybin Sessions

Numbers tell you how many people in a trial improved. They don't tell you what the session was like. For that, a few research teams did something simple: they interviewed participants afterwards and published what they said.

This post draws on two of those studies. One followed people with long-standing depression in Imperial College London's first psilocybin trial. The other followed people with anxiety linked to cancer in a trial at New York University. Both gave strong doses, roughly 3.5 to 4 g of dried mushrooms by common estimates, in a clinic with trained guides.

A note before we start: these are the words of people in supervised clinical trials, chosen and screened by doctors. They describe what those people felt. They are not a promise of what a mushroom will do for anyone else, and nothing here is medical advice.

The London interviews

In Imperial's 2016 trial, 20 people whose depression had not responded to at least two medications each took psilocybin twice, a week apart: 10 mg first, then 25 mg. By the common estimate that 4 g of dried cubensis is about 25 mg of psilocybin, the second session was roughly a 4 g experience. Two experienced clinicians stayed with each person throughout.

Six months later, psychologist Rosalind Watts and colleagues interviewed all 20. They published their analysis in 2017. Two themes ran through almost every interview: moving from disconnection to connection, and from avoiding emotions to accepting them.

"A holiday away from the prison of my brain"

Many described the high-dose session as a sudden change in the quality of their thinking:

  • "It was like a holiday away from the prison of my brain, I was a ball of energy bouncing around the planet, I felt free, carefree, re-energised."
  • "It was like this great shroud had been lifted."
  • "I felt my brain was rebooted, I had the mental agility to overcome problems."

Others spoke of the senses coming back. One participant had once looked at orchids and understood they were beautiful without feeling it. After the dose: "A veil dropped from my eyes, things were suddenly clear, glowing, bright. I looked at plants and felt their beauty."

And many described a sense of connection that reached well past themselves: "I was everybody, unity, one life with 6 billion faces, I was the one asking for love and giving love, I was swimming in the sea, and the sea was me."

The frightening parts

The same interviews are clear that the sessions were not all bliss. One participant called it a "rollercoaster". Others said:

  • "The beauty and the sadness, I was terrified by the depth of emotions."
  • "The hardest thing is to give in to what you're experiencing, it's as if you're in a car heading for the edge of the cliff, and you have to try not to turn the steering wheel."

What stands out is how often people described getting through fear by turning towards it rather than running:

  • "There was this huge terrifying creature with a rifle, and instead of running away, I looked at it, and it wasn't as scary as it had seemed. [My] fear subsided, it suddenly seemed ridiculous, I started laughing. If I had avoided it, it would have got more terrifying."
  • "I got the lesson that you need to go into the scary basement, once you get into it, there is no scary basement to go into [anymore]."

Two participants who said they could not "let go" during the session reported less change afterwards, which is one reason guides talk so much about surrender.

The New York interviews

At NYU, people with anxiety and distress linked to a cancer diagnosis received a single dose of psilocybin (0.3 mg per kilogram of body weight, about 21 mg for a 70 kg person) with psychotherapy before and after. Alexander Belser and colleagues interviewed 13 of them and published their findings in 2017.

Nine of the 13 described losing their usual sense of self. One felt himself "losing the firm grasp on sort of 'me-hood'", including "my past, my relationships, my personality". Another said: "I didn't have a body... I was just like this soul, this entity."

Edna's story

One participant, called Edna in the paper, described a terrifying start, and how she got through it:

"It really hit me very strong. And um, it was terrifying. It was just terrifying. It was, um, I was completely disoriented... I was really, maybe, in the hold of a ship at sea. Rocking. Absolutely nothing, nothing to anchor myself to, nothing, no point of reference, nothing, just lost in space, just crazy, and I was so scared. And then I remembered that Tony and Michelle were right there and suddenly realized why it was so important that I get to know them and they to get to know me. And reached out my hand and just said 'I'm so scared.' And I think it was Tony who took my hand... and said 'It's all right. Just go with it. Go with it.' And um, and I did."

Tony and Michelle were her two therapists, people she had met and come to trust before the session. The researchers note that the distress participants described passed within the session, in a supportive setting, and that no one in the trial needed medication to calm them.

What both studies have in common

Read side by side, the interviews share three things:

  • The high-dose sessions were intense, emotional and often frightening for part of the time.
  • People who leaned into the hard moments, rather than fighting them, tended to describe them as turning points.
  • Nobody was alone. Each person had two trusted, sober, trained people with them, met well in advance.

That third point is the one most often lost when these stories travel. If you take anything from them, take that. Our guides to trip sitting and handling a challenging trip explain how to bring some of that support into a home setting.

How to stay safe on magic mushrooms

  • Never alone. Have a sober sitter you trust in the room for the whole experience.
  • Who should not take mushrooms at all: anyone under 19, pregnant or breastfeeding, with a personal or family history of psychosis, schizophrenia or bipolar disorder, or with a heart condition.
  • Medications. Lithium combined with psychedelics has been linked to seizures. MAOIs and tramadol carry serious risks, and antidepressants can blunt or change the effects. Read psilocybin and medications and talk to a doctor. Never stop a medication on your own.
  • Start far lower. Know how your body responds to small amounts first, and wait at least two hours before even thinking about more.
  • If it gets hard, our guide to handling a challenging trip explains what helps. Call 911 for chest pain, trouble breathing, a seizure, or anyone in danger.
  • No driving, and remember psilocybin remains a controlled substance in Canada. Our safety guide has the full list.

These were measured, single doses given in a clinic. For what science knows about going higher, read beyond 5 grams. One of the earliest high-dose studies was the Good Friday Experiment of 1962.

Sources

What the research says

Research on psilocybin is still young, and most trials give a measured dose with professional support. Results don't mean any product is safe or effective for you.

This guide is general information, not medical or legal advice. If you have health questions, talk to a health professional.

Your next step

Ready for your first trip?

Not sure where to start? Our starter kits are picked for first-timers. Free shipping across Canada on orders over $130.